Literature DB >> 15381250

Counting on mitogen-activated protein kinases--ERKs 3, 4, 5, 6, 7 and 8.

Marie A Bogoyevitch1, Naomi W Court.   

Abstract

Signal transduction pathways in eukaryotic cells integrate diverse extracellular signals, and regulate complex biological responses such as growth, differentiation and death. One group of proline-directed Ser/Thr protein kinases, the mitogen-activated protein kinases (MAPKs), plays a central role in these signalling pathways. Much attention has focused in recent years on three subfamilies of MAPKs, the extracellular signal regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs) and the p38 MAPKs. However, the ERK family is broader than the ERK1 and ERK2 proteins that have been the subject of most studies in this area. Here we overview the work on ERKs 3 to 8, emphasising where possible their biological activities as well as distinctive biochemical properties. It is clear from these studies that these additional ERKs show similarities to ERK1 and ERK2, but with some interesting differences that challenge the paradigm of the archetypical ERK1/2 MAPK pathway.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381250     DOI: 10.1016/j.cellsig.2004.05.004

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  37 in total

1.  MAPKs' status at early stages of renal carcinogenesis and tumors induced by ferric nitrilotriacetate.

Authors:  Francisco A Aguilar-Alonso; José D Solano; Chabetty Y Vargas-Olvera; Ignacio Pacheco-Bernal; Telma O Pariente-Pérez; María Elena Ibarra-Rubio
Journal:  Mol Cell Biochem       Date:  2015-02-28       Impact factor: 3.396

Review 2.  The ERK cascade: a prototype of MAPK signaling.

Authors:  Hadara Rubinfeld; Rony Seger
Journal:  Mol Biotechnol       Date:  2005-10       Impact factor: 2.695

3.  Neuroplasticity and second messenger pathways in antidepressant efficacy: pharmacogenetic results from a prospective trial investigating treatment resistance.

Authors:  Chiara Fabbri; Concetta Crisafulli; Raffaella Calati; Diego Albani; Gianluigi Forloni; Marco Calabrò; Rosalba Martines; Siegfried Kasper; Joseph Zohar; Alzbeta Juven-Wetzler; Daniel Souery; Stuart Montgomery; Julien Mendlewicz; Alessandro Serretti
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-04       Impact factor: 5.270

4.  The maximal size of protein to diffuse through the nuclear pore is larger than 60kDa.

Authors:  Ruiwen Wang; Michael G Brattain
Journal:  FEBS Lett       Date:  2007-06-12       Impact factor: 4.124

Review 5.  Excitation-transcription coupling in skeletal muscle: the molecular pathways of exercise.

Authors:  Kristian Gundersen
Journal:  Biol Rev Camb Philos Soc       Date:  2010-10-06

Review 6.  The role of scaffold proteins in JNK signalling.

Authors:  W Engström; A Ward; K Moorwood
Journal:  Cell Prolif       Date:  2009-11-17       Impact factor: 6.831

7.  Expression of developmental-stage-specific genes in the gilthead sea bream Sparus aurata L.

Authors:  Carmen García Fernández; Chrysoula Roufidou; Efthimia Antonopoulou; Elena Sarropoulou
Journal:  Mar Biotechnol (NY)       Date:  2012-10-02       Impact factor: 3.619

8.  Dictyostelium Erk2 is an atypical MAPK required for chemotaxis.

Authors:  David J Schwebs; Miao Pan; Nirakar Adhikari; Nick A Kuburich; Tian Jin; Jeffrey A Hadwiger
Journal:  Cell Signal       Date:  2018-03-15       Impact factor: 4.315

9.  EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin.

Authors:  Haitao Ji; Ji Wang; Heinz Nika; David Hawke; Susan Keezer; Qingyuan Ge; Bingliang Fang; Xuexun Fang; Dexing Fang; David W Litchfield; Kenneth Aldape; Zhimin Lu
Journal:  Mol Cell       Date:  2009-11-25       Impact factor: 17.970

10.  Local knockdown of ERK2 in the adult mouse brain via adeno-associated virus-mediated RNA interference.

Authors:  Barbara Di Benedetto; Barbara Di Benedetto; Benedikt Wefers; Wolfgang Wurst; Ralf Kühn
Journal:  Mol Biotechnol       Date:  2008-12-04       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.